The trial will assess STAR0602 as a monotherapy in patients with advanced antigen-rich solid tumours, including PD-1 refractory and rare tumours. Credit: National Cancer Institute on Unsplash.

Marengo Therapeutics has dosed the first participant in the Phase I/II START-001 clinical trial of STAR0602, its new T cell receptor (TCR) Vβ directed antibody-fusion molecule.

The open-label, multi-centre trial has been designed for assessing the preliminary clinical activity, safety, and tolerability of STAR0602 as a monotherapy in patients with advanced, antigen-rich solid tumours, including PD-1 refractory and rare tumours.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It includes both a Phase I dose escalation segment and a Phase II dose expansion part.

In the Phase I dose escalation portion, STAR0602 will be given intravenously in advanced solid tumours patients for evaluating its safety/tolerability profile and for determining the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D).

STAR0602 at RP2D will be given to advanced, antigen-rich solid tumour patients for further assessing its preliminary clinical activity and safety in the Phase II dose expansion part.

See Also:

Currently, the trial is enrolling participants at US cancer research institutes, including Mass General Hospital (MGH)/Harvard Medical School, and the National Cancer Institute (NCI) of National Institutes of Health (NIH).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

To support further expansion of the trial, additional top cancer centres are also planned to join these clinical sites.

Marengo CEO Zhen Su said: “The initiation of our first clinical trial with STAR0602 is an important milestone for Marengo and our selective T cell-targeted STAR platform.

“The START-001 trial leverages a deep biology-driven study design to address high unmet clinical needs in patients for whom PD-1 therapies are no longer effective.

“Our clinical development approach utilises a biomarker-enriched, tumour-agnostic strategy that offers a much-needed novel approach to cancer drug development.”